



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100**ACCESSION NO : 0251WL001531****PATIENT ID : KHUSF191287251****CLIENT PATIENT ID: 012312190017****ABHA NO :****AGE/SEX : 36 Years Female****DRAWN : 19/12/2023 09:16:00****RECEIVED : 19/12/2023 10:55:26****REPORTED : 20/12/2023 16:53:47**

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC**MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE****BLOOD COUNTS, EDTA WHOLE BLOOD**

HEMOGLOBIN (HB)	11.2 Low	12.0 - 15.0	g/dL
METHOD : CYANIDE FREE DETERMINATION			
RED BLOOD CELL (RBC) COUNT	3.73 Low	3.8 - 4.8	mil/ μ L
METHOD : ELECTRICAL IMPEDANCE			
WHITE BLOOD CELL (WBC) COUNT	4.80	4.0 - 10.0	thou/ μ L
METHOD : ELECTRICAL IMPEDANCE			
PLATELET COUNT	207	150 - 410	thou/ μ L
METHOD : ELECTRONIC IMPEDANCE			

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	35.0 Low	36 - 46	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	94.0	83 - 101	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.9	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.9	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	15.2 High	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	25.2		
MEAN PLATELET VOLUME (MPV)	10.4	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			

WBC DIFFERENTIAL COUNT

NEUTROPHILS	60	40 - 80	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
LYMPHOCYTES	30	20 - 40	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
MONOCYTES	08	2 - 10	%

Dr. Akansha Jain
Consultant Pathologist

Page 1 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100**ACCESSION NO : 0251WL001531****PATIENT ID : KHUSF191287251****CLIENT PATIENT ID: 012312190017****ABHA NO :****AGE/SEX : 36 Years Female****DRAWN : 19/12/2023 09:16:00****RECEIVED : 19/12/2023 10:55:26****REPORTED : 20/12/2023 16:53:47**

Test Report Status	Final	Results	Biological Reference Interval	Units
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
EOSINOPHILS		02	1 - 6	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
BASOPHILS		00	0 - 2	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
ABSOLUTE NEUTROPHIL COUNT		2.88	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		1.44	1.0 - 3.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.38	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.10	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0 Low	0.02 - 0.10	thou/ μ L
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		2.1		

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia (>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain
Consultant Pathologist

Page 2 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100ACCESSION NO : **0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY**MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE****GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD**

HBA1C	5.0	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
-------	-----	--	---

METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG)	96.8	< 116.0	mg/dL
--------------------------------	------	---------	-------

METHOD : CALCULATED PARAMETER

Dr. Akansha Jain
Consultant Pathologist

Page 3 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**

PATIENT NAME : KHUSHBOO SHUKLA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251WL001531

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status Final

Results

Biological Reference Interval

Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD

E.S.R 10 0 - 20 mm at 1 hr

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods,falsely increasing results.
4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition;
2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin;
3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr. Akansha Jain
Consultant Pathologist

Page 4 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 77500005807050

PATIENT NAME : KHUSHBOO SHUKLA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251WL001531

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status Final

Results

Biological Reference Interval **Units**

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE O

METHOD : TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain
Consultant Pathologist

Page 5 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 77500005807050



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100**ACCESSION NO : 0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY**MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE****GLUCOSE FASTING,FLUORIDE PLASMA**

FBS (FASTING BLOOD SUGAR)	85	74 - 99	mg/dL
METHOD : GLUCOSE OXIDASE			

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)	117	70 - 140	mg/dL
METHOD : GLUCOSE OXIDASE			

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL	187	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE			

TRIGLYCERIDES

TRIGLYCERIDES	96	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : LIPASE/GPO-PAP NO CORRECTION			

HDL CHOLESTEROL

HDL CHOLESTEROL	55	< 40 Low >/=60 High	mg/dL
METHOD : DIRECT CLEARANCE METHOD			

CHOLESTEROL LDL

CHOLESTEROL LDL	113 High	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
-----------------	-----------------	--	-------

NON HDL CHOLESTEROL

NON HDL CHOLESTEROL	132 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED PARAMETER			

Dr. Akansha Jain
Consultant Pathologist

Page 6 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India

Patient Ref. No. 77500005807050



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS :** C000049066AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100ACCESSION NO : **0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status	Final	Results	Biological Reference Interval	Units
VERY LOW DENSITY LIPOPROTEIN		19.2	</= 30.0	mg/dL
CHOL/HDL RATIO		3.4	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO		2.1	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk Risk >6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A. CAD with > 1 feature of high risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80

Dr. Akansha Jain
Consultant Pathologist

Page 7 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 77500005807050



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS :** C000049066AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100**ACCESSION NO :** 0251WL001531**PATIENT ID :** KHUSF191287251**CLIENT PATIENT ID:** 012312190017**ABHA NO :****AGE/SEX :** 36 Years Female**DRAWN :** 19/12/2023 09:16:00**RECEIVED :** 19/12/2023 10:55:26**REPORTED :** 20/12/2023 16:53:47**Test Report Status** Final **Results** **Biological Reference Interval** **Units**

Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.**LIVER FUNCTION PROFILE, SERUM**

BILIRUBIN, TOTAL	0.23	0 - 1	mg/dL
METHOD : DIAZO WITH SULPHANILIC ACID			
BILIRUBIN, DIRECT	0.08	0.00 - 0.25	mg/dL
METHOD : DIAZO WITH SULPHANILIC ACID			
BILIRUBIN, INDIRECT	0.15	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	8.0	6.4 - 8.2	g/dL
METHOD : BIURET REACTION, END POINT			
ALBUMIN	4.6 High	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN	3.4	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.4	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	18	0 - 31	U/L
METHOD : TRIS BUFFER NO P5P IFCC / SFBC 37° C			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	18	0 - 31	U/L
METHOD : TRIS BUFFER NO P5P IFCC / SFBC 37° C			
ALKALINE PHOSPHATASE	108	39 - 117	U/L
METHOD : AMP OPTIMISED TO IFCC 37° C			
GAMMA GLUTAMYL TRANSFERASE (GGT)	31	7 - 32	U/L
METHOD : GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC) 37° C			
LACTATE DEHYDROGENASE	274	230 - 460	U/L

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN	10	5.0 - 18.0	mg/dL
METHOD : UREASE KINETIC			

Page 8 Of 18

Dr. Akansha Jain
Consultant Pathologist

View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS :** C000049066AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100**ACCESSION NO :** 0251WL001531**PATIENT ID :** KHUSF191287251**CLIENT PATIENT ID:** 012312190017**ABHA NO :****AGE/SEX :** 36 Years Female**DRAWN :** 19/12/2023 09:16:00**RECEIVED :** 19/12/2023 10:55:26**REPORTED :** 20/12/2023 16:53:47

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

CREATININE, SERUM

CREATININE

0.83

0.6 - 1.2

mg/dL

METHOD : ALKALINE PICRATE NO DEPROTEINIZATION

BUN/CREAT RATIO

BUN/CREAT RATIO

12.05

METHOD : CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID

5.4

2.4 - 5.7

mg/dL

METHOD : URICASE PEROXIDASE WITH ASCORBATE OXIDASE

TOTAL PROTEIN, SERUM

TOTAL PROTEIN

8.0

6.4 - 8.3

g/dL

METHOD : BIURET REACTION, END POINT

ALBUMIN, SERUM

ALBUMIN

4.6 High

3.8 - 4.4

g/dL

METHOD : BROMOCRESOL GREEN

GLOBULIN

GLOBULIN

3.4

2.0 - 4.1

g/dL

ELECTROLYTES (NA/K/CL), SERUM**Dr. Akansha Jain**
Consultant Pathologist

Page 9 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000049066
 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
 AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
 JAIPUR 302017
 9314660100

ACCESSION NO : 0251WL001531
PATIENT ID : KHUSF191287251
CLIENT PATIENT ID: 012312190017
ABHA NO :

AGE/SEX : 36 Years Female
DRAWN : 19/12/2023 09:16:00
RECEIVED : 19/12/2023 10:55:26
REPORTED : 20/12/2023 16:53:47

Test Report Status	Final	Results	Biological Reference Interval	Units
SODIUM, SERUM		140.7	137 - 145	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				
POTASSIUM, SERUM		4.13	3.6 - 5.0	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				
CHLORIDE, SERUM		104.2	98 - 107	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants [SSRI], antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO ₃ ⁻), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)**GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). **Drugs:** corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), **Drugs:** insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

Dr. Akansha Jain
Consultant Pathologist

Page 10 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India



Patient Ref. No. 77500005807050



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100**ACCESSION NO : 0251WL001531****PATIENT ID : KHUSF191287251****CLIENT PATIENT ID: 012312190017****ABHA NO :****AGE/SEX : 36 Years Female****DRAWN : 19/12/2023 09:16:00****RECEIVED : 19/12/2023 10:55:26****REPORTED : 20/12/2023 16:53:47**

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:- Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome **Causes of decreased levels-** Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM- is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM- Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain
Consultant Pathologist

Page 11 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 77500005807050



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251WL001531

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD : GROSS EXAMINATION

APPEARANCE CLEAR

METHOD : GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

PH 5.5 4.7 - 7.5

METHOD : DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY 1.020 1.003 - 1.035

METHOD : IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NEGATIVE

METHOD : PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE NOT DETECTED NEGATIVE

METHOD : GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

METHOD : SODIUM NITROPRUSSIDE REACTION

BLOOD NOT DETECTED NOT DETECTED

METHOD : PEROXIDASE ANTI PEROXIDASE

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD : DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD : EHRlich REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD : NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD : MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 1-2 0-5 /HPF

METHOD : DIPSTICK, MICROSCOPY

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 77500005807050



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100ACCESSION NO : **0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status	Final	Results	Biological Reference Interval	Units
EPITHELIAL CELLS		2-3	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION				
CASTS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
CRYSTALS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
BACTERIA		NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION				
YEAST		NOT DETECTED	NOT DETECTED	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases

Dr. Akansha Jain
Consultant Pathologist

Page 13 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100ACCESSION NO : **0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (<i>Averrhoa carambola</i>) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain
Consultant Pathologist

Page 14 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100ACCESSION NO : **0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status Final**Results****Biological Reference Interval** **Units****CYTOLOGY****MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE****PAPANICOLAOU SMEAR**

TEST METHOD

SAMPLE NOT RECEIVED

Dr. Akansha Jain
Consultant Pathologist

Page 15 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100ACCESSION NO : **0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status Final**Results****Biological Reference Interval** **Units****CLINICAL PATH - STOOL ANALYSIS****MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE****PHYSICAL EXAMINATION,STOOL**

COLOUR

SAMPLE NOT RECEIVED

METHOD : GROSS EXAMINATION

**Dr. Abhishek Sharma**
Consultant Microbiologist

Page 16 Of 18



View Details



View Report

PERFORMED AT :Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India**Patient Ref. No. 77500005807050**



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS : C000049066**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100ACCESSION NO : **0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status Final**Results****Biological Reference Interval****Units****SPECIALISED CHEMISTRY - HORMONE****MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE****THYROID PANEL, SERUM**

T3	108.70	60.0 - 181.0	ng/dL
METHOD : CHEMILUMINESCENCE			
T4	5.20	4.5 - 10.9	µg/dL
METHOD : CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	22.746 High	0.550 - 4.780	µIU/mL
METHOD : CHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of FT4 is more useful in the diagnosis of hypothyroidism. Most

of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1) Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Page 17 Of 18


Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 77500005807050



MC-5726

PATIENT NAME : KHUSHBOO SHUKLA**REF. DOCTOR : SELF****CODE/NAME & ADDRESS :** C000049066AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG
JAIPUR 302017
9314660100ACCESSION NO : **0251WL001531**

PATIENT ID : KHUSF191287251

CLIENT PATIENT ID: 012312190017

ABHA NO :

AGE/SEX : 36 Years Female

DRAWN : 19/12/2023 09:16:00

RECEIVED : 19/12/2023 10:55:26

REPORTED : 20/12/2023 16:53:47

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidelines of the American Thyroid association during pregnancy and Postpartum, 2011.
NOTE: It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4. TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

****End Of Report****Please visit www.agilusdiagnostics.com for related Test Information for this accession

Page 18 Of 18

Dr. Akansha Jain
Consultant Pathologist



View Details




View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India

**Patient Ref. No. 77500005807050**



Vent Rate : 64 bpm
 PR Interval : 142 ms
 QRS Duration : 86 ms
 QT/QTc Int : 376/383 ms
 P-QRS-T axis : 60.00° 76.00° 73.00°



Axis
 P 60.00°
 QRS 76.00°
 T 73.00°

Dr. NITZ GOYAL
 RMC-388 MD
 Reported By: DR NITZ GOYAL

NAME	MRS. KHUSHBOO SHUKLA	AGE	36Y	SEX	FEMALE
REF BY	MEDIWHEEL	DATE	19/12/2023	REG NO	

ECHOCARDIOGRAM REPORT

WINDOW- POOR/ADEQUATE/GOODVALVE

MITRAL	NORMAL	TRICUSPID	NORMAL
AORTIC	NORMAL	PULMONARY	NORMAL

2D/M-MOD

IVSD mm	8.8	IVSS mm	12.9	AORTA mm	23.0
LVID mm	37.9	LVIS mm	25.4	LA mm	31.8
LVPWD mm	9.5	LVPWS mm	13.2	EF%	60%

CHAMBERS

LA	NORMAL	RA	NORMAL
LV	NORMAL	RV	NORMAL
PERICARDIUM	NORMAL		

DOPPLER STUDY MITRAL

PEAK VELOCITY m/s E/A	0.98/0.59	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
MVA cm2 (PLANIMETERY)		MVA cm2 (PHT)	
MR			

AORTIC

PEAK VELOCITY m/s	1.02	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
AR			

TRICUSPID

PEAK VELOCITY m/s	0.69	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
TR		PASP mmHg	

PULMONARY

PEAK VELOCITY m/s	0.93	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
PR		RVEDP mmHg	

IMPRESSION

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION
- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION : FAIR LV FUNCTION.

Cardiologist



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563



Name : Ms. KHUSHBOO SHUKLA
Age/Gender: 36 Y/Female
Patient ID : 012312190017
BarcodeNo : 10108038
Referred By : Self

Registration No: 71614
Registered : 19/Dec/2023 09:16AM
Analysed : 19/Dec/2023 11:38AM
Reported : 19/Dec/2023 11:38AM
Panel : MEDI WHEEL (ARCOFEMI
HEALTHCARE LTD)

USG: WHOLE ABDOMEN (Female)

- LIVER** : Is normal in size, shape and echogenicity.
The IHBR and hepatic radicals are not dilated.
No evidence of focal echopoor/echorich lesion seen.
Portal vein diameter and Common bile duct normal in size
- GALL BLADDER** : Is normal in size, shape and echotexture. Walls are smooth and regular with normal thickness. There is no evidence of cholelithiasis.
- PANCREAS**: Is normal in size, shape and echotexture. Pancreatic duct is not dilated.
- SPLEEN** : Is normal in size, shape and echogenicity. Spleenic hilum is not dilated.
- KIDNEYS** : Right Kidney:-Size: 93 x 33 mm, Left Kidney:-Size: 90 x 44 mm.
Bilateral Kidneys are normal in size, shape and echotexture.
corticomedullary differentiation is fair and ratio appears normal.
Pelvi calyceal system is normal.No evidence of hydronephrosis/ nephrolithiasis.
- URINARY BLADDER** : Bladder walls are smooth, regular and normal thickness.
: No evidence of mass or stone in bladder lumen.
- UTERUS** : Uterus is anteverted with normal in size shape & echotexture.
Uterine muscular shadows normal echopattern.
Endometrium is normal and centrally placed with size: 6 mm.
No evidence of mass lesion is seen. Size of uterus: 75 x 40 x 30 mm.
- ADNEXA** : Both the ovaries are normal in size shape and echotexture.
No mass lesion/ polycystic ovarian cyst is seen.
- SPECIFIC** : No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.
NO evidence of lymphadenopathy or mass lesion in retroperitoneum.
Visualized bowel loop appear normal.Great vessels appear normal.

IMPRESSION: Ultra Sonography findings are suggestive of: **NORMAL STUDY.**

Page 1 of 2




Dr. Neera Mehta
M.B.B.S., D.M.R.D.



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com



Name : Ms. KHUSHBOO SHUKLA
Age/Gender: 36 Y/Female
Patient ID : 012312190017
BarcodeNo : 10108038
Referred By : Self

Registration No: 71614
Registered : 19/Dec/2023 09:16AM
Analysed : 19/Dec/2023 03:22PM
Reported : 19/Dec/2023 03:22PM
Panel : MEDI WHEEL (ARCOFEMI
HEALTHCARE LTD)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.
Trachea is central.
Bilateral lung field and both CP angle are clear.
Domes of diaphragm are normally placed.
Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

*** End Of Report ***

Page 1 of 1



Dr. Neera Mehta
M.B.B.S., D.M.R.D.
RMCNO.005807/14853

ALPL policy mandates the film records to be maintained for a period of 3 months only. Kindly collect the films before this period.